Cargando…

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients

OBJECTIVES: Low dose, dispersible, levodopa/carbidopa microtablets with an automatic dose dispenser have been developed to facilitate individualized levodopa treatment. The aim of this study was to characterize the pharmacokinetics (PK) of levodopa and carbidopa after microtablet administration, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senek, Marina, Nyholm, Dag, Nielsen, Elisabet I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Pharmacokinetics and Disposition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132549/ https://www.ncbi.nlm.nih.gov/pubmed/29882153 http://dx.doi.org/10.1007/s00228-018-2497-2

Ejemplares similares

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
por: Senek, Marina, et al.
Publicado: (2017)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Population pharmacokinetics of cefotaxime in intensive care patients
por: Swartling, Maria, et al.
Publicado: (2021)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers
por: Otto, M. E., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
por: Orrell, Catherine, et al.
Publicado: (2008)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
por: Grétarsdóttir, Helga María, et al.
Publicado: (2021)

Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers
por: Tanaka, Jun, et al.
Publicado: (2012)

The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
por: El Messaoudi, S., et al.
Publicado: (2016)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Population pharmacokinetics of haloperidol in terminally ill adult patients
por: Franken, L. G., et al.
Publicado: (2017)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers
por: Navaratnam, Visweswaran, et al.
Publicado: (2009)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience
por: Thomas, Ilias, et al.
Publicado: (2019)

Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
por: Yao, Xueting, et al.
Publicado: (2020)

Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
por: Danielak, Dorota, et al.
Publicado: (2017)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation
por: Danielak, Dorota, et al.
Publicado: (2017)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans
por: Yataba, Ikuko, et al.
Publicado: (2015)

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
por: Atiq, Ferdows, et al.
Publicado: (2016)

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
por: Maring, Jan Gerard, et al.
Publicado: (2010)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8fa6il9g0fr3ppln6cha45v8j